Abstract Details
Andrew Lockhart, MB, BAO, BCh, MSc
(University of Oxford)
PRESENTER |
The institution of Dr. Lockhart has received research support from Oxford-Quinnipiac Partnership. The institution of Dr. Lockhart has received research support from European Charcot Foundation. |
Xinran Zhang | Miss Zhang has nothing to disclose. |
Marco Pisa, MD (Nuffield Department of Clinical Neurosciences, University of Oxford) | Dr. Pisa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. |
Aimee Avery (University of Oxford) | The institution of Aimee Avery has received research support from UK MS Society. The institution of Aimee Avery has received research support from US Deparment of Defense. |
Jonathan Pansieri, PhD (University of Oxford) | The institution of Dr. Pansieri has received research support from UK-MS society. The institution of Dr. Pansieri has received research support from Department of Defense US. Dr. Pansieri has received personal compensation in the range of $0-$499 for serving as a member of the Grant review Panel with French National Agency. Dr. Pansieri has received personal compensation in the range of $500-$4,999 for serving as a recipee of Travel Grant with Brain. |
Hal Drakesmith, PhD | Prof. Drakesmith has nothing to disclose. |
Gabriele C. De Luca, MD, DPhil, FAAN (University of Oxford) | Dr. De Luca has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Neurology Academy. Dr. De Luca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Dr. De Luca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. De Luca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. The institution of Dr. De Luca has received research support from NIHR, BRC (Oxford). The institution of Dr. De Luca has received research support from National Health and Medical Research (Australia). The institution of Dr. De Luca has received research support from UK MS Society. The institution of Dr. De Luca has received research support from Oxford-Quinnipiac Partnership. The institution of Dr. De Luca has received research support from US Department of Defense. The institution of Dr. De Luca has received research support from Wellcome ISSF (Oxford). The institution of Dr. De Luca has received research support from Bristol Myers Squibb. The institution of Dr. De Luca has received research support from University of Oxford (John Fell Fund). The institution of Dr. De Luca has received research support from National Health and Medical Research (Australia). Dr. De Luca has a non-compensated relationship as a Editorial board member with MS Journal that is relevant to AAN interests or activities. Dr. De Luca has a non-compensated relationship as a Vice-Chair of Grant Review Panel with UK MS Society that is relevant to AAN interests or activities. Dr. De Luca has a non-compensated relationship as a Steering Group member with MS Academy that is relevant to AAN interests or activities. Dr. De Luca has a non-compensated relationship as a Board of Directors with SEQUINS that is relevant to AAN interests or activities. |